Talbert-Slagle Kristina, DiMaio Daniel
Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06510, USA.
Virology. 2009 Feb 20;384(2):345-51. doi: 10.1016/j.virol.2008.09.033. Epub 2008 Nov 6.
The extremely hydrophobic, 44-amino acid bovine papillomavirus (BPV) E5 protein is the smallest known oncoprotein, which orchestrates cell transformation by causing ligand-independent activation of a cellular receptor tyrosine kinase, the platelet-derived growth factor beta receptor (PDGFbetaR). The E5 protein forms a dimer in transformed cells and is essentially an isolated membrane-spanning segment that binds directly to the transmembrane domain of the PDGFbetaR, inducing receptor dimerization, autophosphorylation, and sustained mitogenic signaling. There are few sequence constraints for activity as long as the overall hydrophobicity of the E5 protein and its ability to dimerize are preserved. Nevertheless, the E5 protein is highly specific for the PDGFbetaR and does not activate other cellular proteins. Genetic screens of thousands of small, artificial hydrophobic proteins with randomized transmembrane domains inserted into an E5 scaffold identified proteins with diverse transmembrane sequences that activate the PDGFbetaR, including some activators as small as 32-amino acids. Analysis of these novel proteins has provided new insight into the requirements for PDGFbetaR activation and specific transmembrane recognition in general. These results suggest that small, transmembrane proteins can be constructed and selected that specifically bind to other cellular or viral transmembrane target proteins. By using this approach, we have isolated a 44-amino acid artificial transmembrane protein that appears to activate the human erythropoietin receptor. Studies of the tiny, hydrophobic BPV E5 protein have not only revealed a novel mechanism of viral oncogenesis, but have also suggested that it may be possible to develop artificial small proteins that specifically modulate much larger target proteins by acting within cellular or viral membranes.
极度疏水的、由44个氨基酸组成的牛乳头瘤病毒(BPV)E5蛋白是已知最小的癌蛋白,它通过导致细胞受体酪氨酸激酶(血小板衍生生长因子β受体,PDGFbetaR)的非配体依赖性激活来协调细胞转化。E5蛋白在转化细胞中形成二聚体,本质上是一个孤立的跨膜片段,直接与PDGFbetaR的跨膜结构域结合,诱导受体二聚化、自磷酸化和持续的促有丝分裂信号传导。只要E5蛋白的整体疏水性及其二聚化能力得以保留,其活性就几乎没有序列限制。然而,E5蛋白对PDGFbetaR具有高度特异性,不会激活其他细胞蛋白。对数千种插入E5支架的具有随机跨膜结构域的小型人工疏水蛋白进行遗传筛选,鉴定出了具有不同跨膜序列的激活PDGFbetaR的蛋白,包括一些小至32个氨基酸的激活剂。对这些新型蛋白的分析为PDGFbetaR激活和一般特异性跨膜识别的要求提供了新的见解。这些结果表明,可以构建和选择能特异性结合其他细胞或病毒跨膜靶蛋白的小型跨膜蛋白。通过使用这种方法,我们分离出了一种似乎能激活人促红细胞生成素受体的44个氨基酸的人工跨膜蛋白。对微小的疏水BPV E5蛋白的研究不仅揭示了一种新的病毒致癌机制,还表明有可能开发出通过在细胞或病毒膜内起作用来特异性调节大得多的靶蛋白的人工小蛋白。